ChondroGene Enters Into Agreement with Kaiser Permanente
Development of Database for Clinical Information
ChondroGene Limited announced that it has entered into an agreement with the Division of Research of the Permanente Medical Group of Northern California, to jointly develop a research database infrastructure that will be used for genomic research. The Permanente Medical Group of Northern California is one of eight multi-specialty physician groups that are part of Kaiser Permanente, America's integrated health care organization with over 8.3 million members in nine states.
When developed, the genomic database will serve as a repository of clinical information generated by Kaiser Permanente researchers for evaluating assays that use ChondroGene's proprietary Sentinel Principle. The principal objectives of the database when implemented are to standardize and achieve consistency in the format of data for future studies. This common format will also facilitate the testing of biospecimens at ChondroGene, as agreed upon by the Kaiser Permanente Division of Research and ChondroGene. The proposed project will draw from Kaiser Permanente researchers' experience in conducting clinical research and managing clinical information, to produce a robust database that will allow Kaiser Permanente researchers to capture, store, retrieve and analyze a broad range of clinical information.
ChondroGene's Sentinel Principle is a unique approach to the diagnosis and staging of disease. If these studies demonstrate that ChondroGene assays are more accurate than traditional assays for certain diseases, they may have a significant impact on the diagnosis and management of those diseases.
Other news from the department business & finance
